Introduction
Tuberculosis (TB) remains a global emergency and continues to kill 1.7 million people globally, each year. During the past decade, there have been significant advances in diagnostic technologies for TB. Increase in both public and private investment and the joint efforts of the World Health Organisation (WHO) and the Foundation for Innovative New Diagnostics (FIND) have facilitated this process [1 ] . FIND are co-developing new diagnostics technologies that are targeted for use at three health system levels: reference laboratory, microscopy centre/peripheral laboratories and primary healthcare level/health post. Such new and improved diagnostics technologies are urgently required for the global fight against the TB epidemic. Liquid media for culture and drug susceptibility testing (DST), molecular line probe assays for screening people at risk of multiple drugresistant TB (MDR-TB), LED microscopy and noncommercial culture and DST have all been endorsed by the WHO since 2007 (Fig. 1) . Endorsement of technology by the WHO combined with FIND's negotiations on pricing Purpose of review Tuberculosis (TB) remains a global emergency and continues to kill 1.7 million people globally each year. Drug-resistant TB is now well established throughout the world and most TB patients are not being screened for drug resistance due to lack of laboratory resources and rapid accurate point-of-care tests. Accurate and rapid diagnosis of TB and drug-resistant TB is of paramount importance in establishing appropriate clinical management and infection control measures. During the past decade, there have been significant advances in diagnostic technologies for TB and drug-resistant TB. The purpose of this article is to review the current data, recommendations and evidence base for these tests.
Recent findings
Second-line drug susceptibility testing (DST) is complex and expensive. Automated liquid culture systems and molecular line probe assays are recommended by the WHO as the current 'gold standard' for first-line DST. Liquid culture DST for aminoglycosides, polypeptides and fluoroquinolones has been shown to have relatively good reliability and reproducibility for diagnosis of extensively drug-resistant TB; however, DST for other second-line drugs (ethionamide, prothionamide, cycloserine, terizidone, paraaminosalicylic acid, clofazimine, amoxicillin-clavulanate, clarithromycin, linezolid) is not recommended. Automated liquid culture systems are currently recommended by the WHO as the 'gold standard' for second-line DST. Summary In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and discuss future prospects for TB diagnostics. Current technologies for the detection of drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the 'holy grail' diagnostic for TB must fulfil all technical specifications for a good point-of-care test, screen for drug resistance concurrently and be adaptable to the various health system levels and to countries with diverse economic status and TB burden. (Fig. 2) . Each year, an estimated half a million MDR-TB cases develop, of which only around 7% are diagnosed. In the 27 highburden MDR-TB countries, only 1% of new TB patients had DST performed in 2008 because of a lack of laboratory capacity [8 ,9] . As a result, patients with drugresistant TB may be inappropriately treated, drug-resistant Mycobacterium tuberculosis strains may spread in the community and amplification of resistance may occur [10 ] . Accurate and rapid diagnosis of drug-resistant TB is of paramount importance in establishing appropriate clinical management and infection control measures [1 ,7 ] .
The 'gold standard' method for M. tuberculosis DST is the indirect 1% proportion method. This method was developed in the 1960s and is still used in many laboratories, especially in developing countries, because it is inexpensive and easily accessible [11] . (ethionamide, prothionamide, cycloserine, terizidone, para-aminosalicylic acid, clofazimine, amoxicillin-clavulanate, clarithromycin, linezolid) is not recommended [12] . Automated liquid culture systems are currently recommended by the WHO as the 'gold standard' for second-line DST [12,13 ,14] . In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of drug-resistant forms of M. tuberculosis and discuss future prospects for TB diagnostics.
Definitions of drug-resistant tuberculosis
MDR-TB is defined as resistance to the two key first-line anti-TB drugs, INH and RIF. XDR-TB is defined as TB caused by strains of M. tuberculosis resistant to at least INH and RIF (i.e. MDR-TB), plus any fluoroquinolone and at least one of three injectable drugs used in anti-TB treatment, capreomycin, kanamycin or amikacin [7 ,8 ] .
Phenotypic drug susceptibility testing
Culture-based or phenotypic DST methods are accurate and inexpensive but are disadvantaged by relying on the growth on M. tuberculosis, rendering them time consuming [15] . Phenotypic DST methods are performed on solid or liquid media as direct or indirect tests. Direct methods are those used directly on patient samples where a set of drug-containing and drug-free media is inoculated directly with a patient specimen. Indirect DST involves inoculation of drug-containing media with a pure culture grown from the original patient specimen [12] . Commercial automated liquid culture DST methods have a relatively short turnaround time (because of sensitive automation and M. tuberculosis's relatively faster growth in liquid compared with solid media) and are highly accurate but are expensive and require specialist equipment [16 ] . The WHO considered evidence for the accuracy and role of a number of noncommercial culture-based methods that utilize widely available and inexpensive laboratory equipment and supplies and recommended selected methods as interim measures while capacity for automated culture DST and/or genotypic DST are being developed [1 ,17 ,18] . Microscopic observation drug susceptibility (MODS) [17 , [19] [20] [21] and colorimetric redox indicator (CRI) [22, 23] 
Commercial liquid culture drug susceptibility testing
The most commonly used commercially available automated liquid culture DST system is the BACTEC MGIT 960 system with the BACTEC MGIT 960 SIRE kit (Becton Dickinson, Franklin Lakes, New Jersey, USA). This is an indirect qualitative method for the detection of first-line drug resistance to streptomycin, INH, RIF and EMB [16 ] . The test, which is performed on M. tuberculosis complex (MTBC) positive culture, takes approximately 4-13 days to obtain a result. The test was developed with critical concentrations for streptomycin (1 mg/ml), INH (0.1 mg/ml), RIF (1 mg/ ml) and EMB (5 mg/ml) that are slightly lower than the critical concentrations used in the proportion method test, in order to avoid false susceptibility results. A PZA DST kit is also available for the MGIT system. The test is based on growth of the MTBC isolate in a drug-containing tube compared with a drug-free tube (growth control). Continuous analysis of fluorescence by the BACTEC MGIT 960 instrument in the drug-containing tube compared with the fluorescence of the growth control tube is used to determine susceptibility results. The instrument automatically interprets these results and reports a susceptible or resistant result [16 ,26] . This method has been demonstrated to be equivalent to the proportion method standard and has been endorsed by the WHO [27, 28, 29 ]. Other nonradiometric automated liquid culture systems capable of M. tuberculosis DST include the BacT/ALERT MB (bioMerieux Inc., Durham, North Carolina, USA) system and the VersaTREK system (Trek Diagnostic Systems, West Lake, Ohio, USA) [28, 30] .
Microscopic observation drug susceptibility
MODS is a liquid culture-based test that can detect members of the MTBC in sputum and can assess INH and RIF susceptibility either directly on sputum samples or indirectly on M. tuberculosis isolates. This method utilizes the markedly faster growth of M. tuberculosis in liquid media than on solid media and the characteristic microscopic cording appearance of M. tuberculosis in liquid media. Cultures containing supplemented Middlebrook 7H9 medium are microscopically examined for microcolonies which can be detected in a median of 7 days. INH and RIF can be incorporated in the testing process to enable MDR-TB detection [21] . Drug-free and drugcontaining media are inoculated with specimens from patients or M. tuberculosis isolates, and cultures are microscopically examined. Growth of M. tuberculosis in drugfree media indicates a positive culture, whereas growth of M. tuberculosis in both drug-free and drug-containing media indicates resistance [17 ,19,21] .
Meta-analysis of direct and combined (direct and indirect) testing of MODS performed by the WHO indicates that the method is 98% sensitive and 99% specific for the detection of RIF resistance and 91% sensitive for INH resistance [18] . High sensitivity and specificity are retained in direct MODS testing. The capability to perform MODS DST directly on sputum samples in a short timescale and the low cost of reagents are advantages of this technique [21] , but the WHO only endorses its implementation at reference laboratory level [18] .
Colorimetric redox indicator methods
The principal of CRI methods is the reduction of a coloured indicator which is added to the culture medium after cultured M. tuberculosis have been exposed to the test antibiotic [30] . Drug resistance is detected by a change in colour of the indicator, which is directly proportional to the number of viable mycobacteria remaining in the medium after exposure to the antibiotic. Different indicators have been evaluated giving comparable results in agreement with the proportion method reference standard. Among the different growth indicators used are the tetrazolium salts XTT and MTT and the redox indicators Alamar blue and resazurin [31] .
Data analysis performed by the WHO showed that CRI methods are highly sensitive and specific for the detection of RIF and INH resistance (98 and 97% sensitive respectively; 99 and 98% specific, respectively) and these methods were endorsed by the WHO in 2010 [18] . CRI methods are indirect tests performed on M. tuberculosis isolates, therefore turnaround time to results is not faster than conventional phenotypic DST [18, 31] .
Nitrate reductase assay
The NRA, also known as the Griess method, is a simple technique based on the capacity of M. tuberculosis to reduce nitrate to nitrite. By incorporating 1 mg/ml potassium nitrate (KNO 3 ) in Lowenstein-Jensen medium, the reduction of nitrate can be detected using the Griess reagent, which produces a coloured reaction [11] . In the presence of antibiotic at the critical concentration, development of a red-pink colour in the medium represents resistance. Susceptible strains lose the capacity to reduce nitrate in the presence of the antibiotic, thus produce no colour. The use of nitrate reduction as an indicator of growth, before colonies can be seen macroscopically, reduces the turnaround time to results compared with conventional methods [11] . The WHO recommends [18] that the NRA be used as a direct test on smear-positive sputum specimens or as an indirect test on M. tuberculosis isolates grown from conventional solid culture. Data on combined (direct and indirect) use showed that the NRA is 97% sensitive and 100% specific for the detection of RIF resistance and 97% sensitive and 99% specific for detection of INH resistance [18] . Diagnostic accuracy data for direct testing alone does not differ significantly. Reagents for NRA are nonproprietary and relatively inexpensive, but indirect testing using NRA is not faster than conventional phenotypic DST using solid media [11, 18] .
Other new and existing phenotypic DST methods, which have not been endorsed by the WHO, are reviewed elsewhere [30] and include the slide-culture technique, mycobacteriophage-based methods including the FastPlaque assay and luciferase reporter phages, the E-test, the thin-layer agar method and the TK medium.
Genotypic drug susceptibility testing
Several molecular diagnostics assays are commercially available for the detection of the MTBC, including the COBAS TaqMan MTB PCR test (Roche Diagnostics, Basel, Switzerland) [32 ] , artus M. tuberculosis PCR kits (Qiagen, Hamburg, Germany) [33] and the Amplified Mycobacterium Tuberculosis Direct (AMTD) test (Gen-Probe Inc., San Diego, California, USA) [34 ] . Recently, commercial and 'in-house' molecular diagnostics assays for the detection of the MTBC and the simultaneous detection of drug resistance have been described [35] [36] [37] [38] [39] [40] . These methods are generally nucleic acid amplification tests (NAATs) and include hybridization assays (e.g. line probe assays), real-time PCR assays (often using molecular beacon probes) and sequencing assays. The most common mutations associated with drug resistance have been described and are publically available on the TB drug resistance mutation database [41 ] . Genotypic DST methods target these well characterized resistance associated mutations to identify drug resistant M. tuberculosis. One of the most important drugs in the treatment of TB is RIF and RIF resistance is particularly suitable for genotypic DST because 95% of RIF resistance associated mutations are present in an 81 bp region of the rpoB gene known as the rifampicin resistance determining region (RRDR) [36] . Molecular detection of resistance to other anti-TB drugs, such as INH and some second-line drugs, is more complex and requires detection of mutations in multiple genes for good correlation with phenotypic results. Accurate genotypic DST for first-line and second-line anti-TB drugs is, therefore, technically challenging. Improved multiplex-PCR technology and improved multianalyte detection technology will make genotypic DST a more powerful technique in future.
Line probe assays
Line probe assays were endorsed by the WHO in 2008 for molecular detection of drug resistance from smearpositive patients at risk of MDR-TB [42] . Two commercial LPAs are currently available: the INNO-LiPA Rif.TB test (Innogenetics NV, Gent, Belgium) and the GenoType MTBDRplus test (Hain Lifescience GmbH, Nehren, Germany) [29 ] . LPAs use a PCR/hybridization technique to identify members of the MTBC while simultaneously identifying drug-resistant strains by detecting the most common single nucleotide polymorphorisms (SNPs) associated with resistance. Metaanalyses have shown that LPAs are highly accurate for the detection of first-line drug resistance, especially in smear-positive sputum specimens [29 ,39,43] . WHO analysis of systematic reviews and meta-analyses showed that LPAs are highly sensitive (!97%) and specific (!99%) for the detection of RIF resistance, alone or in combination with INH (sensitivity !90%; specificity !99%), on isolates of M. tuberculosis and on smearpositive sputum specimens. Accuracy for detection of MDR-TB was 99%, which remained unchanged when RIF resistance alone was used as a proxy marker for MDR-TB [42] . Hain Lifesciences released the GenoType MTBDRsl test in 2009, designed to test for resistance to second-line anti-TB drugs (fluoroquinolones, ethambutol, aminoglycosides and cyclic peptides), and which can be used in combination with the MTBDRplus test to identify XDR-TB [44] [45] [46] . The major advantage of LPAs is that they can be performed directly on smearpositive sputum samples, giving rapid (approximately 5 h) drug susceptibility results without the need for culture. Many laboratories now use LPAs as the primary method for DST on cultured isolates of M. tuberculosis, replacing phenotypic DST [29 ] . The disadvantages of LPAs are that they are labour intensive and require highly trained personnel and dedicated laboratory space and equipment [47] .
Xpert Mycobacterium tuberculosis/rifampicin assay
One of the most promising new point-of-care (POC) diagnostics technologies to be developed in recent years is the GeneXpert (Cepheid, Sunnyvale, California, USA). The GeneXpert machine is a fully automated closed system that performs both sample preparation and realtime PCR, producing results in less than 2 h (Fig. 3) . The Xpert MTB/RIF test, designed for the GeneXpert system, is capable of detecting the MTBC while simultaneously detecting RIF resistance (targeting the RRDR of the rpoB gene). Analytical sensitivity and specificity is 100% according to a recent study using RIF resistant and sensitive M. tuberculosis isolates and nontuberculosis bacteria, fungi and viruses [36] . A clinical validation study of the method was performed using 107 clinical sputum samples from suspected TB cases in Vietnam. The Xpert MTB/RIF test detected 29/29 (100% sensitivity) smear-positive culture-positive cases and 33/39 (84.6% sensitivity) smear-negative culture-positive cases, and M. tuberculosis was not detected in 25/25 (100% specificity) of the culture-negative samples. In the same study, 64 smear-positive culture-positive sputa from patients previously treated for TB in Uganda were tested and the Xpert MTB/RIF test detected 63/64 (98.4% sensitivity) culture-positive cases and nine of nine (100% sensitivity) cases of RIF resistance. RIF resistance was excluded in 55/55 susceptible cases -100% specificity [48 ] . In a recent multicentre (Peru, Azerbaijan, South Africa and India) evaluation study of 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary TB published in the New England Journal of Medicine, a single Xpert MTB/RIF test was 98.2 and 72.5% sensitive on smear-positive (n ¼ 561) and smearnegative (n ¼ 171) TB patients, respectively, and the test was 99.2% specific [49 ] . Compared to phenotypic DST, the MTB/RIF test correctly identified 200 of 205 patients (97.6% sensitive) with RIF-resistant bacteria and 504 of 514 (98.1% specific) with RIF-sensitive bacteria [49 ] . The assay is designed for direct genotypic DST from unprocessed sputum or sediment from a concentrated specimen. Sample reagent is poured into the sample tube, incubated for 15 min, pippetted into the Xpert cartridge and inserted into the GeneXpert machine for processing. Highly trained staff are not required to run the machine or interpret the results [10 ] . The Xpert MTB/RIF test has the potential to be used in moderately equipped laboratories; however, it is unlikely to be used as a POC diagnostic test in the most peripheral settings, like rural health centres, due to poor infrastructure and limited resources [50] . The FIND-negotiated price for a four testing module GeneXpert machine is approximately US$ 17 000 and the Xpert MTB/RIF tests cost approximately US$ 17 per cartridge, but the price is likely to decrease as a result of increased sales related to endorsement of the technology by the WHO in December 2010 [10 ,50] .
There is an urgent need for research on the implementation of the Xpert MTB/RIF test to determine its performance characteristics and the impact it has on patient outcomes when used in a variety of primary healthcare settings covering the wide range of available infrastructure. Other variables that may affect the tests overall performance are HIV prevalence, strain diversity, prevalence of specific drug resistance-conferring mutations, patient-related diagnostic delays and default rates [10 ] .
Future prospects
The ideal TB diagnostic would be a simple, low-technology, rapid, POC test with accurate results that could simultaneously identify drug resistance. In 2009, an expert group led by Medecins Sans Frontieres developed a set of minimum technical specifications for new POC TB tests [51] . No existing test meets all of these specifications, although the Xpert MTB/RIF test meets the majority. Increased availability of funding and growing interest in new TB diagnostics and biomarkers have encouraged the development of several new POC tests for TB including improved serologic assays, hand-held molecular devices, breath-based assays for the detection of volatile organic compounds, microchip technologies and proteomics-based and metabolomics-based tests [29 ] . As POC test technology advances, new POC TB and drug-resistant TB tests reach the market and competition increases, prices for such tests should reduce significantly [10 ,50,52] .
Conclusion
Current technologies for the detection of drug-resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the 'holy grail' TB diagnostic test that fulfils all technical specifications for a good POC test may be developed. Until then, different DST methods are required, suitable for countries with diverse economic status and TB burden and for the various health system levels.
